Disease Info Card

Hemolytic-uremic Syndrome

Information about Hemolytic-uremic Syndrome: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Hemolytic-uremic Syndrome

Most recent studies have shown that Hemolytic-uremic Syndrome shares some biological mechanisms with acute-kidney-injury, anemia, anemia-hemolytic, colitis, diarrhea, disease-of-capillaries, escherichia-coli-infections, hemorrhagic-colitis, hypertensive-disease, infective-disorder, kidney-diseases, kidney-failure, kidney-failure-acute, kidney-failure-chronic, purpura, purpura-thrombotic-thrombocytopenic, thrombocytopenic-purpura, thrombosis, thrombotic-microangiopathies, uremia-syndrome.

Among the many pathways, these few ones have gauged particular interests from scientists studying Hemolytic-uremic Syndrome, and have been seen in publications frequently: Cell Activation, Cell Death, Cell Proliferation, Coagulation, Complement Activation, Diuresis, Excretion, Fibrinolysis, Glomerular Filtration, Hemostasis, Immune Response, Inflammatory Response, Localization, Pathogenesis, Platelet Activation, Platelet Aggregation, Secretion, Swimming, Transport, Virulence

Quite a number of genes have been found to play important roles in Hemolytic-uremic Syndrome, such as ADAMTS13, C3, CAPG, CD46, CFH, CFI, HRH4, HSPB8, SH3BP4, ST8SIA2, STX1A, STX2, TNF, UBN1, VWF, ZFP36. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.